Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study
Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its ...
Cassava shares sink on plans to stop Alzheimer's drug studies
(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...
Cassava to stop trials of Alzheimer's drug after late-stage study failure
(Reuters) -Cassava Sciences said on Monday it will stop all trials of its Alzheimer's disease drug after it failed a ...
Cassava Sciences: Probably The End Of The Saga
Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...
Cassava Sciences Faces Reality After Simufilam's Phase 3 Failure
Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...
Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...
BioSpace4d
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III
Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...
FY2024 EPS Estimate for Cassava Sciences Reduced by Analyst
Research analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Cassava Sciences in a research report issued on Tuesday, November 26th. HC Wainwright analyst V. Bernardino ...
FierceBiotech5d
Cassava flunks phase 3 Alzheimer's test, triggering early end of 2nd trial and stock crash
Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...
STAT5d
Cassava Sciences and its Alzheimer’s drug are done. The damage lingers
The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
Cassava Sciences' stock fell after Phase 3 simufilam trial failed to meet key endpoints, prompting the discontinuation of its ...
Cassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer’s drug flops
Shares in the pharmaceutical company fell a staggering 85% on Monday after it reported disappointing Phase 3 results.